KALA · Kala Pharmaceuticals Inc

-

Please sign in to comment on KALA

1 Comment

Admin

4 years ago

Kala Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 35.3% below its 200 day moving average.

From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.5.

Kala Pharmaceuticals, Inc's total revenue rose by 89.7% to $2M since the same quarter in the previous year.

Its net income has dropped by 41.7% to $-31M since the same quarter in the previous year.

Finally, its free cash flow fell by 43.5% to $-26M since the same quarter in the previous year.

Based on the above factors, Kala Pharmaceuticals, Inc gets an overall score of 2/5.

CurrencyCode	USD
ISIN	US4831192020
Sector	Healthcare
Exchange	NASDAQ
Industry	Biotechnology

Beta	-1.72
Market Cap	22M
PE Ratio	None
Target Price	15
Dividend Yield	None

ABOUT

Kala Pharmaceuticals Inc

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA · Kala Pharmaceuticals Inc

-

Kala Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Kala Pharmaceuticals Inc using a moving average strategy